Literature DB >> 10350553

Spinal cord noradrenergic dynamics in diabetic and hypercortisolaemic states.

M S Bitar1, K T Bajic, T Farook, M I Thomas, C W Pilcher.   

Abstract

Disorders of pain sensation including spontaneous pain, allodynia and hyperalgesia are commonly seen in neuropathic diabetic patients. A wealth of evidence indicates that spinal monoamine systems are implicated in pain modulation but whether abnormalities in these systems underlay such disorders is unclear. The present study was therefore initiated to investigate spinal noradrenergic dynamics during diabetes. Spinal release of norepinephrine (NE) represented by 3-methoxy-4-hydroxyphenylglycol (MHPG)/NE ratio was markedly suppressed in 30-day streptozotocin (STZ)-treated diabetic male and female rats. The density of [3H] p-aminoclonidine binding sites and the level of expression of mRNA encoding for alpha2A-adrenoceptor subtype were also reduced as a function of diabetes. In contrast, an increase in the density of [3H] prazosin binding to spinal synaptosomal membranes was evident in these animals. Clonidine-induced elevation in nociceptive threshold was attenuated in diabetics. Control animals subjected to chronic treatment with a supraphysiological dose of glucocorticoid (GC) exhibited a neurochemical pattern which is similar in many respects to that produced by the diabetic state. Both insulin and the GC receptor blocker, RU 486, restored most of the neurochemical and behavioural abnormalities of diabetes. Overall, the present study supports the concept that a diabetes-related deficit in spinal noradrenergic dynamics may be a reflection of an overactivity of the hypothalamic-pituitary-adrenal axis. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10350553     DOI: 10.1016/s0006-8993(99)01284-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

Review 1.  Diabetic neuropathic pain: Physiopathology and treatment.

Authors:  Anne K Schreiber; Carina Fm Nones; Renata C Reis; Juliana G Chichorro; Joice M Cunha
Journal:  World J Diabetes       Date:  2015-04-15

2.  Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord.

Authors:  Ting-Ting Zhang; Rui Xue; Shi-Yong Fan; Qiong-Yin Fan; Lei An; Juan Li; Lei Zhu; Yu-Hua Ran; Li-Ming Zhang; Bo-Hua Zhong; Yun-Feng Li; Cai-Ying Ye; You-Zhi Zhang
Journal:  J Neuroinflammation       Date:  2018-06-07       Impact factor: 8.322

3.  Impaired noradrenaline homeostasis in rats with painful diabetic neuropathy as a target of duloxetine analgesia.

Authors:  Jun Kinoshita; Yukari Takahashi; Ayako M Watabe; Kazunori Utsunomiya; Fusao Kato
Journal:  Mol Pain       Date:  2013-11-27       Impact factor: 3.395

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.